Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subclinical-dose esketamine for bronchoscopy in elderly patients
ChiCTR2100053528Phase 4Recruiting
- Sponsor
- Shunde Hospital, Southern Medical University
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in major depressive disorder (MDD), post-operative cognitive decline (POCD) and Delayed postoperative recovery (DPR) (2 arms), sponsored by Shunde Hospital, Southern Medical University. Primary endpoints: Depression score, Incidence of postoperative cognitive dysfunction and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)post-operative cognitive decline (POCD)Delayed postoperative recovery (DPR)
Beyond the preview
Go deeper on ChiCTR2100053528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053528.